Exact Mass: 607.0816

Exact Mass Matches: 607.0816

Found 36 metabolites which its exact mass value is equals to given mass value 607.0816, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

UDP-α-D-N-Acetylglucosamine disodium

(2R,3R,4R,5S,6R)-3-(Acetylamino)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl [(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen diphosphoric acid (non-preferred name)

C17H27N3O17P2 (607.0816)


Uridine diphosphate-N-acetylglucosamine (uridine 5-diphosphate-GlcNAc, or UDP-Glc-NAc) is an acetylated aminosugar nucleotide. UDP-GlcNAc is the donor substrate for modification of nucleocytoplasmic proteins at serine and threonine residues with N-acetylglucosamine (O-GlcNAc). Nutrient sensing in mammals is done through the hexosamine biosynthetic pathway (HSP), which produces uridine 5-diphospho-N-acetylglucosamine (UDP-Glc-NAc) as its end product. Mammals respond to nutrient excess by activating O-GlcNAcylation (addition of O-linked N-acetylglucosamine). O-GlcNAc addition (and removal) is key to histone remodeling, transcription, proliferation, apoptosis, and proteasomal degradation. This nutrient-responsive signaling pathway also modulates important cellular pathways, including the insulin signaling cascade in. Alterations in O-GlcNAc metabolism are associated with various human diseases including diabetes mellitus and neurodegeneration. (PMID: 16317114) Due to the chemical makeup of UDP-GlcNAc, it is well positioned to serve as a glucose sensor in that it is a high-energy compound that requires and/or responds to glucose, amino acid, fatty acid and nucleotide metabolism for synthesis. Elevated levels of O-GlcNAc have an effect on insulin-stimulated glucose uptake. (PMID: 12678487). Uridine 5-diphosphate-GlcNAc (UDP-Glc-NAc )respond to nutrient excess to activate O-GlcNAcylation (addition of O-linked N-acetylglucosamine) in the hexosamine signaling pathway (HSP). O-GlcNAc addition (and removal) is key to histone remodeling, transcription, proliferation, apoptosis, and proteasomal degradation. This nutrient-responsive signaling pathway also modulates important cellular pathways, including the insulin signaling cascade in. Alterations in O-GlcNAc metabolism are associated with various human diseases including diabetes mellitus and neurodegeneration. (PMID: 16317114) Acquisition and generation of the data is financially supported in part by CREST/JST.

   

UDP-N-Acetyl-D-galactosamine

[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-methylol-tetrahydropyran-2-yl] [[(2R,3S,4R)-5-(2,4-diketopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] hydrogen phosphate

C17H27N3O17P2 (607.0816)


A UDP-sugar having N-acetyl-D-galactosamine as the sugar component. Acquisition and generation of the data is financially supported in part by CREST/JST.

   

UDP-N-acetyl-D-mannosamine

[({[(2S,3R,4S,5S)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(3R,4S,5R,6S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid

C17H27N3O17P2 (607.0816)


UDP-N-acetyl-D-mannosamine is involved in teichoic acid (poly-glycerol) biosynthesis pathway and enterobacterial common antigen biosynthesis pathway. It serves as both enzymatic reactants and products in those two pathways. In teichoic acid (poly-glycerol) biosynthesis pathway, UDP-N-acetyl-mannosamine is synthesized from UDP-N-acetyl-glocasamine by UDP-N-acetylglucosamine 2-epimerase, encoded by the mnaA gene. UDP-N-acetyl-D-mannosamine is involved in teichoic acid (poly-glycerol) biosynthesis pathway and enterobacterial common antigen biosynthesis pathway. It serves as both enzymatic reactants and products in those two pathways.

   

Uridine diphosphate-N-acetylgalactosamine

N-[2-({[({[3,4-dihydroxy-5-(4-hydroxy-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidate

C17H27N3O17P2 (607.0816)


Uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc) is a sugar donor metabolite, transferring N-acetylgalactosamine (GalNAc, an O-glycan) from UDP-GalNAc to serine and threonine residues, forming an alpha-anomeric linkage in a reaction catalyzed by enzymes known as UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferases. The addition of GalNAc to serine or threonine represents the first committed step in mucin biosynthesis. O-Glycans impart unique structural features to mucin glycoproteins and numerous membrane receptors, and resistance to thermal change and proteolytic attack in a number of diverse proteins. O-Linked carbohydrate side chains function as ligands for receptors, lymphocyte and leukocyte homing, and as signals for protein sorting (PMID: 12634319). Animal studies suggest that overactivity of the hexosamine pathway, resulting in increased UDP-hexosamines (i.e. UDP-GalNAc) is an important mechanism by which hyperglycemia causes insulin resistance. However, to date, human studies concerning the role of the hexosamine pathway in hyperglycemia-induced insulin resistance are scarce and restricted to measurements of glutamine fructose-6-phosphate amidotransferase (GFAT) enzyme activity. Both positive and negative correlations between GFAT activity in human muscle tissue from patients with type 2 DM and glucose disposal rate have been reported (PMID: 12414889). Uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc) is a sugar donor metabolite, transferring N-acetylgalactosamine (GalNAc, an O-glycan) from UDP-GalNAc to serine and threonine residues, forming an alpha anomeric linkage in a reaction catalyzed by enzymes known as UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferases; addition of GalNAc to serine or threonine represents the first committed step in mucin biosynthesis. O-glycans impart unique structural features to mucin glycoproteins and numerous membrane receptors, and resistance to thermal change and proteolytic attack in a number of diverse proteins. O-linked carbohydrate side chains function as ligands for receptors; lymphocyte and leukocyte homing and as signals for protein sorting. (PMID: 12634319)

   

UDP-N-acetyl-alpha-D-galactosamine

(2R,3R,4R,5R,6R)-3-(Acetylamino)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl [(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen diphosphoric acid (non-preferred name)

C17H27N3O17P2 (607.0816)


This compound belongs to the family of Pyrimidine Nucleotide Sugars. These are pyrimidine nucleotides bound to a saccharide derivative through the terminal phosphate group.

   

L-AMP

{[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}[2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazole-4-carbonyloxy]phosphinic acid

C21H18N7O9PS2 (607.0345)


   

Uridine 5-diphospho-N-acetylgalactosamine

Uridine 5-diphospho-N-acetylgalactosamine

C17H27N3O17P2 (607.0816)


   

Uridine 5-diphospho-N-acetylglucosamine

Uridine 5-diphospho-N-acetylglucosamine

C17H27N3O17P2 (607.0816)


   

Uridine-5-diphospho-N-acetylgalactosamine disodium salt

Uridine-5-diphospho-N-acetylgalactosamine disodium salt

C17H27N3O17P2 (607.0816)


   

Uridine-5-diphospho-N-acetylglucosamine sodium salt

Uridine-5-diphospho-N-acetylglucosamine sodium salt

C17H27N3O17P2 (607.0816)


   

Uridine-5-diphosphoacetylgalactosamine

Uridine-5-diphosphoacetylgalactosamine

C17H27N3O17P2 (607.0816)


   

Uridine-5-diphosphoacetylglucosamine

Uridine-5-diphosphoacetylglucosamine

C17H27N3O17P2 (607.0816)


   

UUridine-5-diphosphoacetylglucosamine

UUridine-5-diphosphoacetylglucosamine

C17H27N3O17P2 (607.0816)


   

Uridine-5-diphospho-N-acetylgalactosamine

Uridine-5-diphospho-N-acetylgalactosamine

C17H27N3O17P2 (607.0816)


   

URIDINE 5'-DIPHOSPHO-N-ACETYLGALACTOSAMINE

URIDINE 5'-DIPHOSPHO-N-ACETYLGALACTOSAMINE

C17H27N3O17P2 (607.0816)


   

URIDINE 5'-DIPHOSPHO-N-ACETYLGLUCOSAMINE

URIDINE 5'-DIPHOSPHO-N-ACETYLGLUCOSAMINE

C17H27N3O17P2 (607.0816)


   

Uridine diphosphate-N-acetylglucosamine

Uridine diphosphate-N-acetylglucosamine

C17H27N3O17P2 (607.0816)


   

Uridine diphosphate-N-acetylgalactosamine

Uridine diphosphate-N-acetylgalactosamine

C17H27N3O17P2 (607.0816)


   

UDP-GlcNAc

UDP-N-acetyl-alphaD-glucosamine

C17H27N3O17P2 (607.0816)


   

Carbonylchlorohydrido[bis(2-(diphenylphosphinoethyl)amino]ruthenium(II), Min.98 Ru-MACHO

Carbonylchlorohydrido[bis(2-(diphenylphosphinoethyl)amino]ruthenium(II), Min.98 Ru-MACHO

C29H30ClNOP2Ru (607.0534)


   

(CHLOROMETHYL)METHYLBIS(PENTAFLUOROPHENYL)SILANE

(CHLOROMETHYL)METHYLBIS(PENTAFLUOROPHENYL)SILANE

C32H17ClCoN8 (607.0597)


   

Spiro[3-carboxy-4-{(4-[1,2,3]thiadiazol-4-YL-phenyl)-amino-carbonyl}-5-[3,4-dichloro-phenyl]-tetrahydrofuran-2,2-5-methyl-indan-1,3-dione]

Spiro[3-carboxy-4-{(4-[1,2,3]thiadiazol-4-YL-phenyl)-amino-carbonyl}-5-[3,4-dichloro-phenyl]-tetrahydrofuran-2,2-5-methyl-indan-1,3-dione]

C29H19Cl2N3O6S (607.0372)


   

Uridine diphosphate N-acetylglucosamine

Uridine diphosphate N-acetylglucosamine

C17H27N3O17P2 (607.0816)


   

[[5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazole-4-carboxylate

[[5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazole-4-carboxylate

C21H18N7O9PS2 (607.0345)


   

uridine diphosphate N-acetylmannosamine

uridine diphosphate N-acetylmannosamine

C17H27N3O17P2 (607.0816)


   

Uridine diphospho-N-acetylglucosamine

Uridine diphospho-N-acetylglucosamine

C17H27N3O17P2 (607.0816)


   

URIDINE-diphosphATE-N-acetylglucosamine

URIDINE-diphosphATE-N-acetylglucosamine

C17H27N3O17P2 (607.0816)


A UDP-amino sugar having N-acetyl-alpha-D-glucosamine as the amino sugar component.

   

UDP-N-acetyl-alpha-D-mannosamine

UDP-N-acetyl-alpha-D-mannosamine

C17H27N3O17P2 (607.0816)


   

[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-methylol-tetrahydropyran-2-yl] [[(2R,3S,4R)-5-(2,4-diketopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] hydrogen phosphate

[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-methylol-tetrahydropyran-2-yl] [[(2R,3S,4R)-5-(2,4-diketopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] hydrogen phosphate

C17H27N3O17P2 (607.0816)


   

Uridine-diphosphate-N-acetylgalactosamine

Uridine-diphosphate-N-acetylgalactosamine

C17H27N3O17P2 (607.0816)


   

UDP-N-acetyl-alpha-D-galactosamine

UDP-N-acetyl-alpha-D-galactosamine

C17H27N3O17P2 (607.0816)


A UDP-N-acetyl-D-galactosamine in which the anomeric centre of the galactosamine moiety has alpha-configuration.

   

UDP-N-acetylhexosamine

UDP-N-acetylhexosamine

C17H27N3O17P2 (607.0816)


   

DS-1001b

DS-1001b

C29H29Cl3FN3O4 (607.1208)


DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity[1][2][3].

   

n-{2-[({[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}ethanimidic acid

n-{2-[({[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}ethanimidic acid

C17H27N3O17P2 (607.0816)


   

n-[(3r,4r,5r,6r)-2-[({[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(3r,4r,5r,6r)-2-[({[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C17H27N3O17P2 (607.0816)


   

n-[(2r,3r,4r,5s,6r)-2-[({[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

n-[(2r,3r,4r,5s,6r)-2-[({[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]ethanimidic acid

C17H27N3O17P2 (607.0816)